Return exactly one rewritten English science news headline for the original title below. Maximum 12 words. Output plain text only. Do not use HTML, Markdown, quotes, labels, explanations, bullets, numbering, or multiple options. Original title: Research spotlight: A new standard to better align implantable brain devices with users’ needs

Gabriel Lázaro-Muñoz, PhD, JD, and Amanda R. Merner, PhD, of the Health Technology Performance Lab within the Mass General Brigham Neuroscience Institute, are the authors of a paper published in The American Journal of Psychiatry, “Implantable Neuromodulation Devices in Psychiatry: Human Fidelity and Implementation Challenges.”

Q: What challenges or unmet needs make this study important?

Implantable brain devices—from deep brain stimulation to a new generation of brain-computer interfaces—can help people with severe, treatment-resistant psychiatric and neurological conditions or loss of function (such as paralysis or blindness). Despite the United States’ heavy investment in building these devices and the systems to deliver them, there isn’t a shared, measurable way to tell whether they are meeting the needs and expectations of the people and systems involved.

All too often, good technology that works in the lab fails to reach or be a good fit for “stakeholders,” such as patients, clinicians and healthcare systems. Establishing a way to measure “human fidelity” in the development and implementation of implantable brain devices is necessary to promote trust, access and adoption of neurotechnology.

Q: What central question(s) were you investigating?

We asked whether it’s possible to define and then measure “human fidelity”: how well any given implantable brain device aligns with its stakeholders’ needs and expectations. For example, is the device safe, effective and acceptable for different groups?

While most people would agree that developers should keep patients, clinicians and families top of mind, we wanted a principle that could be woven into the design and development of neurotechnology. That meant asking whether “alignment with the human” could be treated as a concrete property of a device and its surrounding workflows and messaging, rather than a vague aspiration or a one-time checkbox. Just as engineers treat performance requirements like scalability, if “human fidelity” could be measured, it could be benchmarked, compared across devices and improved over time.

Q: What methods or approach did you use?

We synthesized the published literature with roughly a decade of empirical neuroethics research by our team and others into a single organizing concept. Our data foundation included everything from more than 300 in-depth interviews with patients, caregivers, researchers, clinicians, funders, device companies and health insurance providers to other research approaches, including policy analysis, embedded observation within active device trials and public perception surveys on neurotechnology. This work spanned several device types and conditions, including depression, obsessive-compulsive disorder, Tourette syndrome, Parkinson’s disease, dystonia and essential tremor. We drew those threads together to define the concept of “Human Fidelity” and to map pressing alignment gaps.

Q: What did you find?

We introduced a standard we call Human Fidelity and defined it as “the measurable degree to which a device, its access workflows and associated messaging are aligned with the empirically determined needs and expectations of key stakeholders across the full development and clinical translation pipeline.” The central idea is to treat Human Fidelity as a performance variable—much like reliability or scalability in systems engineering—rather than a values statement.

We then identified five domains where the gap between devices and stakeholders is most pressing: Access and Uptake, Invasiveness, Identity and Agency, Patient-Centered Outcomes and Long-term Device Maintenance. For each, we offered concrete recommendations for developers and trial teams.

Q: What are the real-world implications, particularly for patients?

The ultimate goal is to design devices, trials and clinical implementation pathways that patients can trust, access and are more likely to adopt: clear paths to treatment, clear communication about what an implant involves, attention to how a device may affect a person’s sense of self and autonomy, outcomes that matter in daily life and protections for what happens after a study ends—including maintenance for the device a patient’s health now depends on. Our proposed framework offers a shared, measurable target that clinicians and developers can strive toward to benefit more people.

Q: What part of this work feels most meaningful to you personally?

The most meaningful part has been listening to patients and families describe their experiences in their own words, including the challenges they faced, their support needs and what it was like to make decisions about, and live with, brain devices. Those conversations were humbling and emphasized how difficult, yet critical, it is to place people at the center of health technology development. Putting forth the concept of Human Fidelity is our attempt to make that responsibility concrete and durable. If this new standard helps more patients receive a device that genuinely fits their lives, the years behind our research will have been worth it.

Paper cited: Lázaro-Muñoz, G., Merner, A.R. “Implantable Neuromodulation Devices in Psychiatry: Human Fidelity and Implementation Challenges.” The American Journal of Psychiatry. DOI: 10.1176/appi.ajp.20251187

Funding: This paper was supported by grants from the National Institutes of Health (NIH), including the NIH BRAIN Initiative (R01MH133657). This work was also informed by previously funded NIH grants (R01MH114654 and R01MH121371).

Disclosures: The authors report no financial relationships with commercial interests.